References
- Centers for Disease Control. National diabetes fact sheet. United States, 2005. Available at http://www.ndep.nih.gov/diabetes/pubs/2005_National_Diabetes_Fact_Sheet.pdf [Last accessed June 17, 2008]
- American Diabetes Association. Economic costs of diabetes in the U.S. in 2007. Diabetes Care 2008;31:596-615
- Booya F, Bandarian F, Larijani B, et al. Potential risk factors for diabetic neuropathy: a case control study. BMC Neurology 2005;5:24
- Argoff CE, Cole BE, Fishbain DA, et al. Diabetic peripheral neuropathic pain: clinical and quality of life issues. Mayo Clinic Proceedings 2006;81:3-11
- Hall G, Carroll D, Parry D, et al. Epidemiology and treatment of neuropathic pain: the UK primary care perspective. Pain 2006;122:156-62
- Boulton AJM, Vinik AI, Arezzo JC, et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 2005;28:956-62
- Boulton AJ. Management of diabetic peripheral neuropathy. Clin Diabetes 2005;23:9-15
- Greene DA. Presentation, diagnosis, and classification of diabetic neuropathy in older adults. Ann Long-Term Care 2000;8:51-8
- Vinik EJ, Hayes C, Oglesby A, et al. Identification of factors in the nerve fiber specific quality of life (QOL-DN) inventory that reflect QOL and health status. Program and abstracts from the 64th Scientific Sessions of the American Diabetes Association, June 4-8, 2004; Orlando, Florida. Abstract 1212-P
- Jensen MP, Chodroff MJ, Dworkin RH. The impact of neuropathic pain on health-related quality of life. Neurology 2007;68:1178-82
- Vinik AI, Park TS, Stansberry KB, et al. Diabetic neuropathies. Diabetologia 2003;43:957-73
- Le TK, Able SL, Lage MJ. Resource use among patients with diabetes, diabetic neuropathy, or diabetes with depression. Cost Eff Resour Alloc 2006;4:18
- Zhao Y, Ye W, Boye, KS, et al. Prevalence of other diabetes-associated complications and co-morbidities and its impact on healthcare charges among patients with diabetic neuropathy. J Diabetes Complicat. Available online at http://dx.doi.org/10.1016/j.jdiacomp.2008.09.001 (Accessed January 2009)
- Zhao Y, Ash AS, Ellis RP, et al. Predicting pharmacy costs and other medical costs using diagnoses and drug claims. Med Care 2005;43:34-43
- Pope GC, Liu CF, Ellis RP, et al. Principal inpatient diagnostic cost group models for Medicare risk adjustment. Final report to the Health Care Financing Administration under Contract No 50095-048. Waltham, MA: Health Economics Research, February, 1999
- Pope GC, Kautter J, Ellis RP, et al. Risk adjustment of Medicare capitation payments using the CMS-HCC model. Health Care Financ Rev 2004;25:119-41
- Zhao Y, Kuo T, Weir S, et al. Healthcare costs and utilization for Medicare beneficiaries with Alzheimer's. BMC Health Serv Res 2008;8:108
- Kuo T, Zhao Y, Weir S, et al. Implications of comorbidity on costs for patients with Alzheimer disease. Med Care 2008;46:839-46
- UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998;352:837-53
- Diabetes Control and Complications Trial (DCCT) Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86